Zobrazeno 1 - 10
of 112
pro vyhledávání: ''
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Zsuzsanna Varga, Thomas Ruhstaller, Ulrike Perriard, Dirk Klingbiel, Tilman T. Rau, Jean-Christophe Tille, Beat Thuerlimann, Hanne Hawle, Qiyu Li, Wolfram Jochum
Publikováno v:
Varga, Zsuzsanna; Li, Qiyu; Jochum, Wolfram; Perriard, Ulrike; Rau, Tilman; Tille, Jean-Christoph; Hawle, Hanne; Klingbiel, Dirk; Thuerlimann, Beat; Ruhstaller, Thomas (2019). Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Scientific reports, 9(1), p. 13534. Springer Nature 10.1038/s41598-019-49638-4
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-responsive patients. An accurate determination of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509ed0eb6c511bb431eb561f8c240921
Autor:
I.A.M. Mandjes, Esther H. Lips, Bas B. Koolen, Lennart Mulder, Sjoerd Rodenhuis, Jelle Wesseling, L. Wessels, J. J. de Ronde
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Intrinsic subtypes are widely accepted for the classification of breast cancer. Lacking gene expression data, surrogate classifications based on immunohistochemistry (IHC) have been proposed. A recent St. Gallen consensus meeting recommends to use th
Publikováno v:
Cancer Immunology, Immunotherapy
To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast
Autor:
Qiongchao Jiang, Bing Ou, Fengtao Liu, Jiyi Yao, Hui Zhi, Shao-Yun Hao, Xin Pan, Xiao-yun Xiao, Zizhuo Zhao, Bao-Ming Luo
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background There is an unmet need for specific and sensitive imaging techniques to assess the efficacy of breast cancer therapy, particularly Her-2-expressing cancers. Ultrasonic microbubbles are being developed for use as diagnostic and therapeutic
Autor:
Oumar Camara, Carola Rabenstein, Cornelia Jörke, Klaus Hoeffken, Ingo B. Runnebaum, Katharina Pachmann, Anne Egbe, U. Hammer
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135(4):643-647
In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many
Autor:
M E, Cazzaniga, L, Cortesi, A, Ferzi, L, Scaltriti, F, Cicchiello, M, Ciccarese, S, Della Torre, F, Villa, M, Giordano, C, Verusio, M, Nicolini, A R, Gambaro, L, Zanlorenzi, E, Biraghi, L, Legramandi, E, Rulli, Valter, Torri
Publikováno v:
Breast Cancer Research and Treatment
Purpose: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm thes
Autor:
Reiner Laus, Lisa Do, John R. Lombardo, Ulrike Dirmeier, Katie Dalpozzo, Alain Delcayre, Peter L. Schoonmaker, Ryan Rountree, Robin Steigerwald, Stefanie Mandl, Thierry Giffon
Publikováno v:
Cancer Immunology, Immunotherapy
MVA-BN®-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN®-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary m
Autor:
David Miles, José Baselga, Sandra M. Swain, Adam Knott, Graham Ross, Dino Amadori, Patrapim Sunpaweravong, Emma Clark, Vladimir Semiglazov
Publikováno v:
Breast Cancer Research and Treatment
Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conduc